🇵🇹 Daily Portugal news for expats & investors — FREE Subscribe
Sign in Subscribe

Pharma

Bial Shelves the BIA 28-6156 Parkinson Phase 2 Trial After the Trofa Pharma Reads No Efficacy Signal at the Primary Endpoint — Five-Year Disease-Modification Programme Folded as the Compound Misses Its Placebo Comparator

Bial Shelves the BIA 28-6156 Parkinson Phase 2 Trial After the Trofa Pharma Reads No Efficacy Signal at the Primary Endpoint — Five-Year Disease-Modification Programme Folded as the Compound Misses Its Placebo Comparator

Bial-Portela & C. (Bial), the Trofa-based family-owned pharmaceutical company that remains Portugal's largest independent drug developer, confirmed on Monday 9 June 2026 that it has discontinued the clinical development of BIA 28-6156 , the...
The Portugal Brief
Hovione Names António Almeida and Marco Gil Co-CEOs as Jean-Luc Herbeaux Steps Down on 21 May After Three-Year Run — Both Incoming Executives Carry 19-Year Tenures and the Permanent CEO Search Is Already Open

Hovione Names António Almeida and Marco Gil Co-CEOs as Jean-Luc Herbeaux Steps Down on 21 May After Three-Year Run — Both Incoming Executives Carry 19-Year Tenures and the Permanent CEO Search Is Already Open

Hovione, Portugal's flagship pharmaceutical contract-development-and-manufacturing group, will replace Jean-Luc Herbeaux with a two-person co-CEO bridge on 21 May 2026. António Almeida (CFO) and Marco Gil (SVP Sales & Marketing) take the top job jointly; both joined Hovione in 2007.
The Portugal Brief
Farminveste's 2025 Net Profit Quintuples to €58.7 Million on the Alloga Logifarma Divestment — €908.6 Million Revenue, €51.6 Million EBITDA as the ANF-Controlled Holding Reweights Around Glintt, CUF and HMR International

Farminveste's 2025 Net Profit Quintuples to €58.7 Million on the Alloga Logifarma Divestment — €908.6 Million Revenue, €51.6 Million EBITDA as the ANF-Controlled Holding Reweights Around Glintt, CUF and HMR International

Farminveste's 2025 net profit hit €58.7M, nearly quintupling 2024's €11.2M, on the May-2025 sale of 51% of Alliance Healthcare (Alloga Logifarma). Volume of business €908.6M (+7.6%); EBITDA €51.6M (+10%); continuing ops €26M; discontinued ops €73.8M from the divestment.
The Portugal Brief